From C-Reactive Protein to Interleukin-6 to Interleukin-1: Moving Upstream To Identify Novel Targets for Atheroprotection.
暂无分享,去创建一个
[1] S. Akira,et al. Faculty Opinions recommendation of Inflammation. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis. , 2016 .
[2] B. Amundsen,et al. Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. , 2016, European heart journal.
[3] R. Giugliano,et al. Achievement of Dual Low-Density Lipoprotein Cholesterol and High-Sensitivity C-Reactive Protein Targets More Frequent With the Addition of Ezetimibe to Simvastatin and Associated With Better Outcomes in IMPROVE-IT , 2015, Circulation.
[4] P. Libby,et al. Targeting Interleukin-1&bgr; Reduces Leukocyte Production After Acute Myocardial Infarction , 2015, Circulation.
[5] G. Filippatos,et al. Anti‐Inflammatory Treatment With Colchicine in Acute Myocardial Infarction: A Pilot Study , 2015, Circulation.
[6] D. Celermajer,et al. Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome , 2015, Journal of the American Heart Association.
[7] A. Warnatsch,et al. Neutrophil extracellular traps license macrophages for cytokine production in atherosclerosis , 2015, Science.
[8] M. Nahrendorf,et al. Neutrophil-macrophage communication in inflammation and atherosclerosis , 2015, Science.
[9] C. Kahn,et al. Diabetes primes neutrophils to undergo NETosis, which impairs wound healing , 2015, Nature Medicine.
[10] Manuel A. R. Ferreira,et al. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis , 2015, The lancet. Diabetes & endocrinology.
[11] C. Herder,et al. Interleukin-1 receptor antagonist: friend or foe to the heart? , 2015, The lancet. Diabetes & endocrinology.
[12] John W McEvoy,et al. An analysis of calibration and discrimination among multiple cardiovascular risk scores in a modern multiethnic cohort. , 2015, Annals of internal medicine.
[13] A. Abbate,et al. Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? , 2015, European heart journal.
[14] Clinton S. Robbins,et al. Monocyte fate in atherosclerosis. , 2015, Arteriosclerosis, thrombosis, and vascular biology.
[15] P. Libby,et al. Moderate Hypoxia Potentiates Interleukin-1&bgr; Production in Activated Human Macrophages , 2014, Circulation research.
[16] Paul M Ridker,et al. Anti-inflammatory therapies for cardiovascular disease. , 2014, European heart journal.
[17] P. Ridker,et al. Effects of an Antisense Oligonucleotide Inhibitor of C‐Reactive Protein Synthesis on the Endotoxin Challenge Response in Healthy Human Male Volunteers , 2014, Journal of the American Heart Association.
[18] N. Frangogiannis,et al. The inflammatory response in myocardial injury, repair, and remodelling , 2014, Nature Reviews Cardiology.
[19] Guangping Li,et al. Association between local interleukin-6 levels and slow flow/microvascular dysfunction , 2014, Journal of Thrombosis and Thrombolysis.
[20] Daniel F. Freitag,et al. Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis. , 2014, European heart journal.
[21] M. Pepys,et al. Infusion of Pharmaceutical-Grade Natural Human C-Reactive Protein Is Not Proinflammatory in Healthy Adult Human Volunteers , 2014, Circulation research.
[22] I. McInnes,et al. Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study , 2013, Annals of the rheumatic diseases.
[23] A. Hall,et al. The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study , 2013, European heart journal.
[24] B. V. Van Tassell,et al. Targeting interleukin-1 in heart disease. , 2013, Circulation.
[25] P. Libby,et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. , 2013, American heart journal.
[26] H. Crijns,et al. Elevated Levels of Circulating DNA and Chromatin Are Independently Associated With Severe Coronary Atherosclerosis and a Prothrombotic State , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[27] Traci L. Marin,et al. Sterol Regulatory Element Binding Protein 2 Activation of NLRP3 Inflammasome in Endothelium Mediates Hemodynamic-Induced Atherosclerosis Susceptibility , 2013, Circulation.
[28] P. Tak,et al. Pro-atherogenic lipid changes and decreased hepatic LDL receptor expression by tocilizumab in rheumatoid arthritis. , 2013, Atherosclerosis.
[29] G. Biondi-Zoccai,et al. Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study]. , 2013, The American journal of cardiology.
[30] J. Eikelboom,et al. Low-dose colchicine for secondary prevention of cardiovascular disease. , 2013, Journal of the American College of Cardiology.
[31] M. Nahrendorf,et al. Leukocyte Behavior in Atherosclerosis, Myocardial Infarction, and Heart Failure , 2013, Science.
[32] B. Engelmann,et al. Thrombosis as an intravascular effector of innate immunity , 2012, Nature Reviews Immunology.
[33] P. Libby,et al. Effects of Interleukin-1&bgr; Inhibition With Canakinumab on Hemoglobin A1c, Lipids, C-Reactive Protein, Interleukin-6, and Fibrinogen: A Phase IIb Randomized, Placebo-Controlled Trial , 2012, Circulation.
[34] Jos W. M. van der Meer,et al. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases , 2012, Nature Reviews Drug Discovery.
[35] Jennifer G. Robinson,et al. Comparison of the Framingham and Reynolds Risk Scores for Global Cardiovascular Risk Prediction in the Multiethnic Women's Health Initiative , 2012, Circulation.
[36] Jennifer G. Robinson,et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis , 2012, The Lancet.
[37] A. Mantovani,et al. Cancer-related inflammation: common themes and therapeutic opportunities. , 2012, Seminars in cancer biology.
[38] P. Libby,et al. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). , 2011, American heart journal.
[39] P. Libby,et al. Progress and challenges in translating the biology of atherosclerosis , 2011, Nature.
[40] C. Dinarello,et al. Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. , 2011, Blood.
[41] S. Yamasaki,et al. Effects of the anti-interleukin-6 receptor antibody, tocilizumab, on serum lipid levels in patients with rheumatoid arthritis , 2011, Rheumatology International.
[42] S. Shoelson,et al. Type 2 diabetes as an inflammatory disease , 2011, Nature Reviews Immunology.
[43] Egil Lien,et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals , 2010, Nature.
[44] P. Kovanen,et al. Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation , 2010, PloS one.
[45] G. Biondi-Zoccai,et al. Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study). , 2010, The American journal of cardiology.
[46] C. Dinarello. Why not treat human cancer with interleukin-1 blockade? , 2010, Cancer and Metastasis Reviews.
[47] J. Danesh,et al. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis , 2010, The Lancet.
[48] P. Hawkins,et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. , 2009, The New England journal of medicine.
[49] Ian J. Brown,et al. Genetic Loci associated with C-reactive protein levels and risk of coronary heart disease. , 2009, JAMA.
[50] J. Liao,et al. Genetically elevated C-reactive protein and ischemic vascular disease , 2009, Current atherosclerosis reports.
[51] Børge G Nordestgaard,et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial , 2009, The Lancet.
[52] P. Ridker. C-reactive protein: eighty years from discovery to emergence as a major risk marker for cardiovascular disease. , 2009, Clinical chemistry.
[53] P. Libby,et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. , 2008, The New England journal of medicine.
[54] 淳一 佐々木. Air Force/Texas Coronary Atherosclerosis Prevention Study , 2008 .
[55] G. Yancopoulos,et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. , 2008, Arthritis and rheumatism.
[56] D. Fearon,et al. Inflammation and cardiovascular disease: role of the interleukin-1 receptor antagonist. , 2008, Circulation.
[57] S. Holland,et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.
[58] Amy Shui,et al. Clinical Relevance of C-Reactive Protein During Follow-Up of Patients With Acute Coronary Syndromes in the Aggrastat-to-Zocor Trial , 2006, Circulation.
[59] F. Martinon,et al. Gout-associated uric acid crystals activate the NALP3 inflammasome , 2006, Nature.
[60] Azra Mahmud,et al. Arterial Stiffness Is Related to Systemic Inflammation in Essential Hypertension , 2005, Hypertension.
[61] U. Singh,et al. C-Reactive Protein Decreases Tissue Plasminogen Activator Activity in Human Aortic Endothelial Cells: Evidence that C-Reactive Protein Is a Procoagulant , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[62] E. Yeh,et al. Release of C-reactive protein in response to inflammatory cytokines by human adipocytes: linking obesity to vascular inflammation. , 2005, Journal of the American College of Cardiology.
[63] J. Jukema,et al. No Effect of C-Reactive Protein on Early Atherosclerosis Development in Apolipoprotein E*3-Leiden/Human C-Reactive Protein Transgenic Mice , 2005, Arteriosclerosis, thrombosis, and vascular biology.
[64] 이영선,et al. 일부 농촌지역 주민의 High Sensitivity C-reactive Protein(hsCRP)과 고혈압의 관련성 , 2005 .
[65] C. Sabin,et al. Transgenic human C-reactive protein is not proatherogenic in apolipoprotein E-deficient mice. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[66] P. Ridker,et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.
[67] B. Cohen,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[68] Paul Schoenhagen,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.
[69] M. Hersberger,et al. Inflammatory Markers at the Site of Ruptured Plaque in Acute Myocardial Infarction: Locally Increased Interleukin-6 and Serum Amyloid A but Decreased C-Reactive Protein , 2005, Circulation.
[70] J. Farmer. Reversal of atherosclerosis with aggressive lipid lowering. , 2005, Current atherosclerosis reports.
[71] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[72] C. Trautwein,et al. Impact of Interleukin-6 on Plaque Development and Morphology in Experimental Atherosclerosis , 2004, Circulation.
[73] G. Firestein,et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist , 2004, The Lancet.
[74] F. Ohsuzu,et al. Lack of Interleukin-1 Receptor Antagonist Modulates Plaque Composition in Apolipoprotein E–Deficient Mice , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[75] F. Martinon,et al. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. , 2004, Immunity.
[76] Lan Li,et al. C-Reactive Protein Accelerates the Progression of Atherosclerosis in Apolipoprotein E–Deficient Mice , 2004, Circulation.
[77] P. Hawkins,et al. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. , 2004, Arthritis and rheumatism.
[78] E. Yeh,et al. Inflammatory Cytokines Stimulated C-Reactive Protein Production by Human Coronary Artery Smooth Muscle Cells , 2003, Circulation.
[79] S. Devaraj,et al. C-Reactive Protein Decreases Prostacyclin Release From Human Aortic Endothelial Cells , 2003, Circulation.
[80] E. Edelman,et al. Increased Thrombosis After Arterial Injury in Human C-Reactive Protein–Transgenic Mice , 2003, Circulation.
[81] M. Seishima,et al. Lack of Interleukin-1&bgr; Decreases the Severity of Atherosclerosis in ApoE-Deficient Mice , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[82] S. Devaraj,et al. C-Reactive Protein Increases Plasminogen Activator Inhibitor-1 Expression and Activity in Human Aortic Endothelial Cells: Implications for the Metabolic Syndrome and Atherothrombosis , 2003, Circulation.
[83] A. Siegbahn,et al. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. , 2001, JAMA.
[84] J. Manson,et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. , 2001, JAMA.
[85] Paul M. Ridker,et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. , 2001, The New England journal of medicine.
[86] A. Kastrati,et al. Protective role against restenosis from an interleukin-1 receptor antagonist gene polymorphism in patients treated with coronary stenting. , 2000, Journal of the American College of Cardiology.
[87] D. Crossman,et al. Interleukin-1 Receptor Antagonist Expression in Human Endothelial Cells and Atherosclerosis , 2000, Arteriosclerosis, thrombosis, and vascular biology.
[88] James T. Willerson,et al. Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells , 2000, Circulation.
[89] P. Ridker,et al. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. , 2000, Circulation.
[90] P. Ridker,et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. , 2000, The New England journal of medicine.
[91] S. Humphries,et al. Inflammation, obesity, stress and coronary heart disease: is interleukin-6 the link? , 2000, Atherosclerosis.
[92] J. Gunn,et al. Temporal and spatial distribution of interleukin-1β in balloon injured porcine coronary arteries , 1999 .
[93] N. Camp,et al. Interleukin-1 receptor antagonist gene polymorphism and coronary artery disease. , 1999, Circulation.
[94] M. Entman,et al. Cardiac myocytes produce interleukin-6 in culture and in viable border zone of reperfused infarctions. , 1999, Circulation.
[95] M. Pfeffer,et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. , 1998, Circulation.
[96] R J Glynn,et al. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. , 1998, Circulation.
[97] P. Ridker,et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. , 1998, Circulation.
[98] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[99] S. Thompson,et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.
[100] G. Bearman,et al. Thermal detection of cellular infiltrates in living atherosclerotic plaques: possible implications for plaque rupture and thrombosis , 1996, The Lancet.
[101] A. Takeshita,et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor. , 1996, The Journal of clinical investigation.
[102] A. Rebuzzi,et al. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. , 1994, The New England journal of medicine.
[103] W. Weintraub,et al. Elevation of C-reactive protein in "active" coronary artery disease. , 1990, The American journal of cardiology.
[104] P. Libby,et al. Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. , 1988, The Journal of clinical investigation.
[105] R. Cotran,et al. Interleukin 1 acts on cultured human vascular endothelium to increase the adhesion of polymorphonuclear leukocytes, monocytes, and related leukocyte cell lines. , 1985, The Journal of clinical investigation.
[106] R. Cotran,et al. Interleukin 1 (IL-1) induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells , 1984, The Journal of experimental medicine.
[107] A. Maseri,et al. Measurement of serum C-reactive protein concentration in myocardial ischaemia and infarction. , 1982, British heart journal.
[108] M. Mccarty. THE OCCURRENCE DURING ACUTE INFECTIONS OF A PROTEIN NOT NORMALLY PRESENT IN THE BLOOD , 1947, The Journal of experimental medicine.
[109] Thomas Francis,et al. SEROLOGICAL REACTIONS IN PNEUMONIA WITH A NON-PROTEIN SOMATIC FRACTION OF PNEUMOCOCCUS , 1930, The Journal of experimental medicine.
[110] J. Kastelein,et al. Controversies in cardiovascular medicine C-reactive protein is a mediator of cardiovascular disease , 2010 .
[111] S. Yusuf,et al. Controversies in cardiovascular medicine C-reactive protein is a bystander of cardiovascular disease , 2010 .
[112] E. Barrett-Connor,et al. Association of interleukin-6 and C-reactive protein with subclinical carotid atherosclerosis (the Rancho Bernardo Study). , 2007, The American journal of cardiology.
[113] Susanne Hempel,et al. Web Appendix , 2007 .
[114] J. Gunn,et al. Temporal and spatial distribution of interleukin-1 beta in balloon injured porcine coronary arteries. , 1999, Cardiovascular research.